Cardiovascular toxicity of tisagenlecleucel in children and adolescents: analysis of spontaneous reports submitted to FAERS

Cardiovascular toxicity of tisagenlecleucel in children and adolescents: analysis of spontaneous reports submitted to FAERS

BackgroundThe advent of tisagenlecleucel has been a major advance in the pharmacological treatment of relapsed/refractory B-cell acute lymphoblastic leukemia in children and adolescents. However, further research is required to better define its safety profile.ObjectivesTo determine the cardiovascul...

Full description

Saved in:

Bibliographic Details
Main Authors:	Ganggang Wang, Lin Su, Yanjun Liu, Xiaohan Yang, Yi Li, Qi Mei, Wen Gao
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2025-01-01
Series:	Frontiers in Immunology
Subjects:	tisagenlecleucel Adverse Event Reporting System data mining cardiovascular adverse event child
Online Access:	https://www.frontiersin.org/articles/10.3389/fimmu.2025.1499143/full
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Post-Marketing Pharmacovigilance of Canakinumab from the FDA Adverse Event Reporting System (FAERS)
by: Weidong Zhang, et al.
Published: (2025-01-01)

Safety profiles of sevoflurane in pediatric patients: a real-world pharmacovigilance assessment based on the FAERS database
by: Chuang Yang, et al.
Published: (2025-02-01)

A meta-analysis of risk factors for cardiovascular adverse events with anthracycline based chemotherapy in lymphoma patients
by: Bo Dai, et al.
Published: (2025-01-01)

Disproportionality analysis of upadacitinib-related adverse events in inflammatory bowel disease using the FDA adverse event reporting system
by: Shiyi Wang, et al.
Published: (2025-02-01)

Real-world pharmacovigilance of ofatumumab in multiple sclerosis: a comprehensive FAERS data analysis
by: Hui Chen
Published: (2025-01-01)

Associations of Serum Urate and Cardiovascular Events in a Clinical Trial of Interleukin-1β Blockade
by: Nicholas H. Adamstein, MD, et al.
Published: (2025-03-01)

Real-world pharmacovigilance study of drug-induced autoimmune hepatitis from the FAERS database
by: Bu-kun Zhu, et al.
Published: (2025-02-01)

Visit-to-visit lipid variability on long-term major adverse cardiovascular events: a prospective multicentre cohort from the CORE-Thailand registry
by: Chutithep Teekaput, et al.
Published: (2025-01-01)

Hepatitis associated with immune checkpoint inhibitors-based combinations of other therapies: A real-world pharmacovigilance analysis based on the FDA adverse event reporting system (FAERS) database
by: Zhaohui Li, et al.
Published: (2024-11-01)

Major Adverse Cardiovascular Events in Primary Aldosteronism After Adrenalectomy or Mineralocorticoid Receptor Antagonist Treatment: A Systematic Review and Meta‐Analysis
by: Chien‐Wei Huang, et al.
Published: (2025-02-01)

Cardiovascular safety of Janus kinase inhibitors in inflammatory bowel disease: a systematic review and network meta-analysis
by: Huibin Yang, et al.
Published: (2025-12-01)

A decade-long overview of adverse events in a tertiary surgical service in South Africa
by: H Wain, et al.
Published: (2024-10-01)

Surveillance of Adverse Events Following Varicella Vaccine Immunization in Zhejiang Province, China, from 2020 to 2022
by: Hui Liang, et al.
Published: (2025-01-01)

Impact of statin use on major adverse cardiovascular events in patients with normal stress myocardial perfusion imaging and elevated coronary artery calcium score
by: Yi Hui To, et al.
Published: (2023-02-01)

A multidimensional assessment of adverse events associated with paliperidone palmitate: a real-world pharmacovigilance study using the FAERS and JADER databases
by: Siyu Lou, et al.
Published: (2025-01-01)

Surgical treatment of anomalous aortic origin of the coronary artery in paediatric patients: a Chinese single-center experience
by: Kai Luo, et al.
Published: (2025-01-01)

Antithrombotic therapy in adults with ectatic coronary artery disease: a systematic review and network meta-analysis
by: Alireza Azarboo, et al.
Published: (2025-01-01)

Adverse drug events (ADEs) risk signal mining related to eculizumab based on the FARES database
by: Xi-Feng Wang, et al.
Published: (2025-01-01)

Corrigendum: Adverse drug events (ADEs) risk signal mining related to eculizumab based on the FARES database
by: Xi-Feng Wang, et al.
Published: (2025-02-01)

Safety assessment of rosuvastatin-fenofibrate combination in the treatment of hyperlipidemia based on FDA’s adverse event reporting system database
by: Qun Li, et al.
Published: (2025-02-01)

Increased PD-1 expression in livers associated with PD-1-antibody-induced hepatotoxicity
by: Miro Saarela, et al.
Published: (2025-01-01)

Adverse events in different administration routes of amiodarone: a pharmacovigilance study based on the FDA adverse event reporting system
by: Jingrong Yang, et al.
Published: (2025-01-01)

Efficacy and Safety of Osteoporosis Medication in Renal Transplantation: A Systematic Review and Meta-Analysis
by: Amir Sheikholeslami, et al.
Published: (2024-09-01)

Association between cardiopulmonary bypass duration and early major adverse cardiovascular events after surgical repair of supravalvular aortic stenosis
by: Simeng Zhang, et al.
Published: (2025-01-01)

Association between triglyceride glucose index and adverse cardiovascular prognosis in patients with atrial fibrillation without diabetes: a retrospective cohort study
by: Aobo Gong, et al.
Published: (2025-01-01)

Major adverse cardiovascular events among Black and White Veterans receiving androgen deprivation therapy for prostate cancer: a retrospective cohort study
by: Alexander R. Lucas, et al.
Published: (2025-02-01)

Triglyceride-glucose index predicts adverse cardiovascular events in patients with H-type hypertension combined with coronary heart disease: a retrospective cohort study
by: Changjiang Li, et al.
Published: (2025-01-01)

A post-marketing pharmacovigilance study of triazole antifungals: adverse event data mining and analysis based on the FDA adverse event reporting system database
by: Yalan Tian, et al.
Published: (2025-01-01)

Prognostic Value of the Tricuspid Regurgitation Impact on Outcomes (TRIO) Score in Patients Undergoing Transcatheter Aortic Valve Implantation
by: Jizhong Wang, et al.
Published: (2025-01-01)

Prognosis modelling of adverse events for post-PCI treated AMI patients based on inflammation and nutrition indexes
by: Liu Yang, et al.
Published: (2025-01-01)

Persistent lipoprotein(a) exposure and its association with clinical outcomes after acute myocardial infarction: a longitudinal cohort study
by: Zhenwei Wang, et al.
Published: (2025-12-01)

Acute Infusion-Related Side Effects of Amphotericin B Lipid Complex (ABLC) in Oncohematological Patients: Real-World Data from Brazilian Reference Centers
by: Francelise Bridi Cavassin, et al.
Published: (2024-11-01)

A disproportionality analysis of FDA adverse event reporting system events for misoprostol
by: Li Yang, et al.
Published: (2025-01-01)

Impact of Timing the Combination of Radiotherapy and PD-1 Inhibitors on Outcomes in Patients with Hepatocellular Carcinoma
by: Zhong L, et al.
Published: (2025-01-01)

A real-world Pharmacovigilance study of brodalumab based on the FDA adverse event reporting system
by: Ke He, et al.
Published: (2025-01-01)

The real-world safety of Ofatumumab: a pharmacovigilance analysis based on the FDA adverse event reporting system
by: Yue Zhou, et al.
Published: (2025-01-01)

Relationship between effective blood flow rate and clinical outcomes in maintenance hemodialysis patients: a single-center study
by: Zhoucang Zhang, et al.
Published: (2024-12-01)

Prediction of major adverse cardiovascular events following ST-segment elevation myocardial infarction using cardiac obesity marker—epicardial adipose tissue mass index: a prospective cohort study
by: Zeyan Liu, et al.
Published: (2025-02-01)

The impact of uric acid on acute coronary syndrome prognosis in elderly patients
by: Yifan Li, et al.
Published: (2025-12-01)

Mucocutaneous Adverse Events in Patients With Cancer Treated with the Highly Selective RET Kinase Inhibitor Selpercatinib (LOXO-292)
by: Rachel E. Reingold, MD, et al.
Published: (2025-03-01)